Active Recombinant Mouse Flt1 Protein, Fc-tagged

• Cat.No.: Flt1-7210M
• Product Overview: Recombinant Mouse soluble Vascular Endothelial Growth Factor Receptor-1 (sVEGFR-1(D7) (Tyr23-Asn757) fused with the Fc part of human IgG1 was expressed in insect cells.

Specification

• Description: Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFA, VEGFB and PGF, and plays an essential role in the development of embryonic vasculature, the regulation of angiogenesis, cell survival, cell migration, macrophage function, chemotaxis, and cancer cell invasion. Acts as a positive regulator of postnatal retinal hyaloid vessel regression. May play an essential role as a negative regulator of embryonic angiogenesis by inhibiting excessive proliferation of endothelial cells. Can promote endothelial cell proliferation, survival and angiogenesis in adulthood. Its function in promoting cell proliferation seems to be cell-type specific. Promotes PGF-mediated proliferation of endothelial cells, and proliferation of some types of cancer cells, but does not promote proliferation of normal fibroblasts. Has very high affinity for VEGFA and relatively low protein kinase activity; may function as a negative regulator of VEGFA signaling by limiting the amount of free VEGFA and preventing its binding to KDR. Modulates KDR signaling by forming heterodimers with KDR. Ligand binding leads to the activation of several signaling cascades. Activation of PLCG leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate and the activation of protein kinase C. Mediates phosphorylation of PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase, leading to the activation of phosphatidylinositol kinase and the downstream signaling pathway. Mediates activation of MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. Phosphorylates SRC, YES1 and PLCG, and may also phosphorylate CBL. Promotes phosphorylation of AKT1 and PTK2/FAK1.
• Source: Insect cell
• Species: Mouse
• Tag: Fc
• Form: Lyophilized
• Bio-activity: The activity of sVEGFR-1/Fc was determined by its ability to inhibit the VEGF-dependent proliferation of human umbilical vein endothelial cells. The ED50 for this effect is typically 10-30 ng/mL.
• Molecular Mass: 130 kDa
• AA Sequence: YGSGSKLKVPELSLKGTQHVMQAGQ TLFLKCRGEAAHSWSLPTTVSQEDK RLSITPPSACGRDNRQFCSTLTLDT AQANHTGLYTCRYLPTSTSKKKKAE SSIYIFVSDAGSPFIEMHTDIPKLV HMTEGRQLIIPCRVTSPNVTVTLKK FPFDTLTPDGQRITWDSRRGFIIAN ATYKEIGLLNCEATVNGHLYQTNYL THRQTNTILDVQIRPPSPVRLLHGQ TLVLNCTATTELNTRVQMSWNYPGK ATKRASIRQRIDRSHSHNNVFHSVL KINNVESRDKGLYTCRVKSGSSFQS FNTSVHVYEKGFISVKHRKQPVQET TAGRRSYRLSMKVKAFPSPEIVWLK DGSPATLKSARYLVHGYSLIIKDVT TEDAGDYTILLGIKQSRLFKNLTAT LIVNVKPQIYEKSVSSLPSPPLYPL GSRQVLTCTVYGIPRPTITWLWHPC HHNHSKERYDFCTENEESFILDPSS NLGNRIESISQRMTVIEGTNKTVST LVVADSQTPGIYSCRAFNKIGTVER NIKFYVTDVPNGFHVSLEKMPAEGE DLKLSCVVNKFLYRDITWILLRTVN NRTMHHSISKQKMATTQDYSITLNL VIKNVSLEDSGTYACRARNIYTGED ILRKTEVLVRDSEAPHLLQNLSDYE VSISGSTTLDCQARGVPAPQITWFK NNHKIQQEPGIILGPGNSTLFIERV TEEDEGVYRCRATNQKGAVESAAYL TVQGTSDKSNAASDKTHTCPPCPAP ELLGGPSVFLFPPKPKDTLMISRTP EVTCVVVDVSHEDPEVKFNWYVDGV EVHNAKTKPREEQYNSTYRVVSVLT VLHQDWLNGKEYKCKVSNKALPAPI EKTISKAKGQPREPQVYTLPPSREE MTKNQVSLTCLVKGFYPSDIAVEWE SNGQPENNYKTTPPMLDSDGSFFLY SKLTVDKSRWQQGNVFSCSVMHEAL HNHYTQKSLSLSPGK
• N-terminal Sequence Analysis: SGSKLKD
• Purity: > 95 % by SDS-PAGE and visualised by silver stain
• Stability: Shelf life: one year from despatch.
• Storage: Store lyophilized at 2-8 centigrade for 6 months or at -20 centigrade long term.
  After reconstitution store the antibody undiluted at 2-8 centigrade for one month or (in aliquots) at -20 centigrade long term.
  Avoid repeated freezing and thawing.
• Storage Buffer: PBS, pH 7.4 without stabilizers
• Reconstitution: Restore in water or medium to a concentration not lower than 50 μg/mL. The lyophilised sVEGFR-1/Fc is soluble in water and most aqueous buffers.

Gene Information

• Gene Name: Flt1 FMS-like tyrosine kinase 1 [ Mus musculus (house mouse) ]
• Official Symbol: Flt1
• Synonyms: Flt1; FMS-like tyrosine kinase 1; sFl; Flt-; VEGF; Flt-1; VEGFR; sFlt1; VEGFR1; VEGFR-1; AI323757; vascular endothelial growth factor receptor 1; embryonic receptor kinase 2; tyrosine-protein kinase receptor FLT; vascular permeability factor receptor; EC 2.7.10.1
• Gene ID: 14254
• mRNA Refseq: NM_010228
• Protein Refseq: NP_034358
• UniProt ID: P35969

Reviews

07/08/2019

the FLT1 protein is an excellent choice for researchers due to its high quality, reliability, and the comprehensive technical support provided by the manufacturer.

07/17/2018

The manufacturer of FLT1 protein provides excellent technical support, ensuring that researchers receive prompt assistance and guidance when encountering any challenges or difficulties.

05/27/2016

Researchers can confidently incorporate FLT1 protein into their experiments, knowing that they have access to a reliable resource that will meet their experimental needs effectively.

Q&As

How is FLT1 linked to preeclampsia in pregnancy?

Elevated levels of soluble FLT1 have been associated with preeclampsia, a pregnancy complication. Soluble FLT1 acts as a decoy receptor, reducing the bioavailability of VEGF and contributing to vascular dysfunction.

How does FLT1 contribute to retinal diseases such as diabetic retinopathy?

FLT1 has been implicated in retinal diseases like diabetic retinopathy, where abnormal blood vessel growth can lead to vision impairment. Inhibiting FLT1 may help regulate angiogenesis in such conditions.

How is FLT1 expression regulated in the human body?

FLT1 expression is regulated by various factors, including VEGF itself, as well as hypoxia and inflammation. These factors influence the balance of angiogenic signaling.

Can FLT1 be a biomarker for certain diseases?

Yes, elevated levels of soluble FLT1 have been investigated as potential biomarkers for conditions like preeclampsia, cancer, and certain cardiovascular diseases.

Can FLT1 be targeted for anti-angiogenic therapy?

Yes, targeting FLT1 is a strategy for anti-angiogenic therapy. Inhibiting FLT1 can impede blood vessel formation, limiting the blood supply to tumors and potentially slowing their growth.